DNAJC5 and malaria: The most advanced malaria vaccine, RTS,S/AS01, targets Plasmodium falciparum circumsporozoite protein (CSP; expressed on pre-erythrocytic stages) and moderately reduces the risk of clinical malaria (efficacy 40–70% in different populations) but does not entirely prevent infection in field trials [3].